News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Aegis Therapeutics, LLC Release: First Non-Injectable GLP-1 Analog For Type-2 Diabetes


8/6/2014 10:29:03 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

SAN DIEGO, CA--(Marketwired - August 05, 2014) -

Aegis announced today that it is offering an exclusive license to develop, commercialize, and sell its patented non-invasive exenatide metered nasal spray diabetes drug. Exenatide is a 39-amino acid synthetic peptide GLP-1 analog highly effective in controlling blood glucose levels in Type-2 diabetes. All currently available GLP-1 analogs require injection. The currently marketed injectable form of exenatide, sold under the trademark Byetta®, requires twice daily injections. The Aegis patented Intravail® based formulation of exenatide provides equivalent blood levels using a simple metered nasal spray to replace each of the two daily injections. The total market for GLP-1 analogs is expected to grow to $5 billion within the next few years. As the only non-injectable option for patients seeking to avoid needles, needlestick injuries, and syringe disposal problems, the non-injectable Aegis nasal spray exenatide formulation is poised to achieve significant market share.

For licensing inquiries, please contact Ralph Barry.

About Aegis Therapeutics

Aegis Therapeutics LLC commercializes its patented drug formulation technologies through product-specific licenses. Intravail® drug delivery technology enables non-invasive delivery of a broad range of protein, peptide and non-peptide drugs that can currently only be administered by injection, via the oral, buccal, and intranasal administration routes, and with high bioavailability. Our ProTek® excipients stabilize, prevent aggregation, and reduce unwanted immunogenicity of protein and peptide therapeutics while avoiding oxidative damage caused by polysorbate surfactants.

For more information about Aegis, please visit: http://www.aegisthera.com.


Contact:
Ralph Barry
Chief Business Officer
Aegis Therapeutics LLC
1-858-618-1400 Ext. 102
Email: Email Contact



Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES